215 related articles for article (PubMed ID: 11673505)
1. Preferential blockade of CD8(+) T cell responses by administration of anti-CD137 ligand monoclonal antibody results in differential effect on development of murine acute and chronic graft-versus-host diseases.
Nozawa K; Ohata J; Sakurai J; Hashimoto H; Miyajima H; Yagita H; Okumura K; Azuma M
J Immunol; 2001 Nov; 167(9):4981-6. PubMed ID: 11673505
[TBL] [Abstract][Full Text] [Related]
2. Differential expression of Fas and Fas ligand in acute and chronic graft-versus-host disease: up-regulation of Fas and Fas ligand requires CD8+ T cell activation and IFN-gamma production.
Shustov A; Nguyen P; Finkelman F; Elkon KB; Via CS
J Immunol; 1998 Sep; 161(6):2848-55. PubMed ID: 9743345
[TBL] [Abstract][Full Text] [Related]
3. Induction of lethal graft-versus-host disease by anti-CD137 monoclonal antibody in mice prone to chronic graft-versus-host disease.
Kim W; Kim J; Jung D; Kim H; Choi HJ; Cho HR; Kwon B
Biol Blood Marrow Transplant; 2009 Mar; 15(3):306-14. PubMed ID: 19203721
[TBL] [Abstract][Full Text] [Related]
4. [Immunosuppressive effect of CTLA-4 blockade and regulatory role of CD8 T cells in Th2-mediated humoral immune responses].
Sakurai J
Kokubyo Gakkai Zasshi; 2000 Jun; 67(2):146-54. PubMed ID: 10921238
[TBL] [Abstract][Full Text] [Related]
5. [Study on control of graft-versus-host disease by blocking CD137-CD137L ligand costimulatory pathway in mice].
Li CH; Xu KL; Pan XY; Du B
Zhonghua Xue Ye Xue Za Zhi; 2007 Feb; 28(2):93-7. PubMed ID: 17650668
[TBL] [Abstract][Full Text] [Related]
6. Host T cells resist graft-versus-host disease mediated by donor leukocyte infusions.
Blazar BR; Lees CJ; Martin PJ; Noelle RJ; Kwon B; Murphy W; Taylor PA
J Immunol; 2000 Nov; 165(9):4901-9. PubMed ID: 11046015
[TBL] [Abstract][Full Text] [Related]
7. Kinetics of Th1 and Th2 cytokine production during the early course of acute and chronic murine graft-versus-host disease. Regulatory role of donor CD8+ T cells.
Rus V; Svetic A; Nguyen P; Gause WC; Via CS
J Immunol; 1995 Sep; 155(5):2396-406. PubMed ID: 7650373
[TBL] [Abstract][Full Text] [Related]
8. Study of relieving graft-versus-host disease by blocking CD137-CD137 ligand costimulatory pathway in vitro.
Xu K; Li C; Pan X; Du B
Int J Hematol; 2007 Jul; 86(1):84-90. PubMed ID: 17675273
[TBL] [Abstract][Full Text] [Related]
9. In vivo CD86 blockade inhibits CD4+ T cell activation, whereas CD80 blockade potentiates CD8+ T cell activation and CTL effector function.
Lang TJ; Nguyen P; Peach R; Gause WC; Via CS
J Immunol; 2002 Apr; 168(8):3786-92. PubMed ID: 11937530
[TBL] [Abstract][Full Text] [Related]
10. CD137 ligand prevents the development of T-helper type 2 cell-mediated allergic asthma by interferon-gamma-producing CD8+ T cells.
Polte T; Jagemann A; Foell J; Mittler RS; Hansen G
Clin Exp Allergy; 2007 Sep; 37(9):1374-85. PubMed ID: 17845419
[TBL] [Abstract][Full Text] [Related]
11. CD137-mediated immunotherapy for allergic asthma.
Polte T; Foell J; Werner C; Hoymann HG; Braun A; Burdach S; Mittler RS; Hansen G
J Clin Invest; 2006 Apr; 116(4):1025-36. PubMed ID: 16528411
[TBL] [Abstract][Full Text] [Related]
12. Effect of CD80 and CD86 blockade and anti-interleukin-12 treatment on mouse acute graft-versus-host disease.
Saito K; Yagita H; Hashimoto H; Okumura K; Azuma M
Eur J Immunol; 1996 Dec; 26(12):3098-106. PubMed ID: 8977310
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of Th2-mediated allergic airway inflammatory disease by CD137 costimulation.
Sun Y; Blink SE; Liu W; Lee Y; Chen B; Solway J; Weinstock J; Chen L; Fu YX
J Immunol; 2006 Jul; 177(2):814-21. PubMed ID: 16818735
[TBL] [Abstract][Full Text] [Related]
14. IL-18 prevents the development of chronic graft-versus-host disease in mice.
Okamoto I; Kohno K; Tanimoto T; Iwaki K; Ishihara T; Akamatsu S; Ikegami H; Kurimoto M
J Immunol; 2000 Jun; 164(11):6067-74. PubMed ID: 10820292
[TBL] [Abstract][Full Text] [Related]
15. Infusion of anti-B7.1 (CD80) and anti-B7.2 (CD86) monoclonal antibodies inhibits murine graft-versus-host disease lethality in part via direct effects on CD4+ and CD8+ T cells.
Blazar BR; Sharpe AH; Taylor PA; Panoskaltsis-Mortari A; Gray GS; Korngold R; Vallera DA
J Immunol; 1996 Oct; 157(8):3250-9. PubMed ID: 8871619
[TBL] [Abstract][Full Text] [Related]
16. Differential effect of CTLA4Ig on murine graft-versus-host disease (GVHD) development: CTLA4Ig prevents both acute and chronic GVHD development but reverses only chronic GVHD.
Via CS; Rus V; Nguyen P; Linsley P; Gause WC
J Immunol; 1996 Nov; 157(9):4258-67. PubMed ID: 8892665
[TBL] [Abstract][Full Text] [Related]
17. Conversion of alloantigen-specific CD8+ T cell anergy to CD8+ T cell priming through in vivo ligation of glucocorticoid-induced TNF receptor.
Kim J; Choi WS; Kang H; Kim HJ; Suh JH; Sakaguchi S; Kwon B
J Immunol; 2006 May; 176(9):5223-31. PubMed ID: 16621987
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of graft-versus-host disease by interleukin-2 treatment is associated with altered cytokine production by expanded graft-versus-host-reactive CD4+ helper cells.
Wang MG; Szebeni J; Pearson DA; Szot GL; Sykes M
Transplantation; 1995 Sep; 60(5):481-90. PubMed ID: 7676498
[TBL] [Abstract][Full Text] [Related]
19. Blockade of CTLA-4 signals inhibits Th2-mediated murine chronic graft-versus-host disease by an enhanced expansion of regulatory CD8+ T cells.
Sakurai J; Ohata J; Saito K; Miyajima H; Hirano T; Kohsaka T; Enomoto S; Okumura K; Azuma M
J Immunol; 2000 Jan; 164(2):664-9. PubMed ID: 10623808
[TBL] [Abstract][Full Text] [Related]
20. Breaking of CD8+ T cell tolerance through in vivo ligation of CD40 results in inhibition of chronic graft-versus-host disease and complete donor cell engraftment.
Kim J; Park K; Kim HJ; Kim J; Kim HA; Jung D; Kim HJ; Choi HJ; Choi SY; Seo KW; Cho HR; Kwon B
J Immunol; 2008 Nov; 181(10):7380-9. PubMed ID: 18981161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
